论文部分内容阅读
目的 :对比性观察分析长春瑞滨 +顺铂 (NVB +DDP)方案与环磷酰胺 +阿霉素 +顺铂 (CAP)方案治疗非小细胞肺癌的临床疗效。方法 :4 8例Ⅲ～Ⅳ期NSCLC肺癌采用NVB2 5mg/m2 d1,5iv ;DDP35mg/m2 d1～ 3天联合方案及 5 6例Ⅲ～Ⅳ期NSCLC采用CAP方案。即CTX6 0 0mg/m2 d1天 ,ADM35mg/m2 d1天 ,DDP30mg/m2 d1～ 3天。结果 :NP组 :CR +PR =2 4例 ,有效率 5 0 % ,中位缓解期 5 5个月 ,中位生存期 11个月。CAP组 :CR +PR =2 0例 ,有效率 35 7% ,中位缓解期 4个月。中位生存期 8个月。主要毒副反应 :NP组为骨髓抑制及静脉炎 ,CAP组为消化道反应、脱发、心电图改变。结论 :NP组联合化疗治疗晚期NSCLC疗效较高 ,副作用可以耐受 ,值得临床推广应用
OBJECTIVE: To comparatively observe the clinical effects of vinblastine + cisplatin (NVB + DDP) and cyclophosphamide + doxorubicin + cisplatin (CAP) in the treatment of non-small cell lung cancer. Methods: Forty-eight NSCLC patients with stage Ⅲ-Ⅳ lung cancer were treated with NVB2 5mg / m2 d1,5iv, dDP 35mg / m2 d1 ~ 3 days and 56 cases with stage Ⅲ-Ⅳ NSCLC. That CTX6 0 0 mg / m2 d1 days, ADM35mg / m2 d1 days, DDP30mg / m2 d1 ~ 3 days. Results: NP group: CR + PR = 24 cases, the effective rate of 50%, the median remission of 5 5 months, the median survival of 11 months. CAP group: CR + PR = 20 cases, the effective rate was 35.7%, the median remission 4 months. The median survival of 8 months. The main side effects: NP group of myelosuppression and phlebitis, CAP group of gastrointestinal reactions, hair loss, ECG changes. Conclusion: NP combined with chemotherapy is effective in treating advanced NSCLC and the side effects are tolerable, which is worthy of clinical application